<DOC>
<DOCNO>1051005_business_story_5321053.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Orchid in pact with Mayne

 OUR SPECIAL CORRESPONDENT 

 Mumbai, Oct. 4: Chennai-based Orchid Chemicals amp; Pharmaceuticals Ltd (Orchid) has entered into an exclusive distribution alliance with Mayne Pharma, the injectible speciality pharmaceuticals division of the Mayne Group Ltd (Mayne).

 Under the deal, Mayne will market Orchids select life-saving injectible antibiotic formulations in identified regulated markets of the US, Canada, Europe and Australasia.

 Mayne will fund Orchids development of these products and the profits will be shared between the partners. However, Orchid did not divulge details about this transaction. Orchid will exclusively develop and manufacture a range of injectible antibiotic formulations in specific dosage forms and strengths for distribution and marketing by Mayne. 

 According to Orchid, these products have a current market-size of over $1 billion in the selected markets. 

 The products will be supplied as soon as they are developed. The patented products will be supplied once they go off patent, it added. 

 Orchid recently entered the US market with the generic version of Ceftriaxone, upon its patent expiry. The company plans to expand its presence in the regulated market. 




</TEXT>
</DOC>